INTRODUCTION
Acute lymphoblastic leukemia (ALL)' is no longer thought to represent a single disease entity, and currently there is considerable attention focused on the immunological and biochemical subclassification of this group of diseases. Immunological classification based on the identificationi of bone marrow-derived (B-) and thymus-derived (T-) cell sub-populations has shown that lymphoblasts from 70-80% of patients with ALL lack both B-and T-cell markers (null cells), whereas 20-30% can be shown to be of T-cell origin, and only 2% of all cases are of B-cell type (1) . Recently, the activity of the enzyme adenosine deaminase (ADA) has been shown to have specific importance for the metab-olism of lymphocytes (2) . Tissue distribution studies show that ADA is usually present in all the tissues of the body with the highest activity in lymphocytes (3) and thymocytes (4) . Furthermore, congenital absence ofthis enzyme, which arises as an inborn error ofmetabolism, results in the syndrome of severe combined immunodeficiency (5) (6) (7) (8) . ADA activity has been found to be subnormal in the lymphocytes of patients with chronic lymphocytic leukemia (9, 10, 11) a disease characterized by immunologic impairment and an abnormal proliferation of B cells (12) . We previously demonstrated that the ADA activity of acute leukemia lymphoblasts is greatly increased in comparison with normal lymphocyte levels (3), and this has subsequently been confirmed by other studies (4, 11) . The considerable variation in absolute ADA activity among ALL patients noted previously, and the known immunological heterogeneity of ALL, prompted us to study leukemic lymphoblasts to determine whether a correlation exists between ADA activity and immunological subclasses of ALL.
METHODS
Patient population. Newly diagnosed patients with ALL cared for on the Pediatric Oncology Branch of the National Cancer Institute were studied. The diagnosis of ALL was based on classical clinically accepted criteria (13) . The patients ranged from 1 to 30 yr of age; none had received treatment before the collection of their lymphoblasts.
Cell collection. Lymphoblasts were collected from peripheral blood by leukapheresis at the time of the patient's initial admission. The cells were harvested by dextran (Pharmacia Fine Chemicals Inc., Piscataway, N. J.) sedimentation and stored in Teflon (Du Pont, E. I. de Nemours & Co., Inc., Wilmington, Del.) bags in a viable state in liquid nitrogen with 10% dimethylsulfoxide at -140°C. On the day of the tests, cells were thawed rapidly, washed twice, and placed on a Ficoll-Hypaque density gradient that consisted of 9% Ficoll (Pharmacia Fine Chemicals Inc., Piscataway, N. J.) and 34% Hypaque (Winthrop Laboratories, New York). This techriique allowed nonviable cells to pass through the gradient. 95% of the remaining cell suspension was viable as assessed by trypan blue exclusion.
Preparationi of cell extracts. The separated lymphoblasts were resuspended at 4°C in a 0.15-M phosphate buffer (pH 7.1), and the cell concentration adjusted to 0.5-1.0 x 107/ml before disrupting a 3-ml vol of cells by sonication (45 s at 40 kHz, Biosonic, Bronwill Scientific, Rochester, N. Y.). The suspension was then centrifuged at 800 g for 10 min, and the supernate used for the enzyme assay.
Adentositne deamintase assay. ADA activity was assayed by a modification ofKalckar's technique (14) , on a Gilford, 2,400-2 spectrophotometer (Gilford Instruments Company, Oberlin, Ohio) at 30°C. The sample cuvette contained 0.3 ml adenosine (2 mM) and 2.2 ml 0.15-M phosphate buffer (pH 7.1). The reaction was started by the addition of 0.5-ml cell extract, and followed by recording the initial decrease in OD at 265 nm, which was linear for at least 5 mim. Protein estimations of the same cell extract were performed by the techniique of Lowry et al. (15) . 1 U of ADA activity is defined as the amount of enzyme activity which produces a decrease in OD of 0.010/ min under the conditions described (3, 16) .
B-and l'-cell markers. Erythrocyte-(E) rosette formation was measured by a previously described method with neuraminidase pretreated sheep erythrocytes (17) . Erythrocyte antibody complement (EAC) rosettes were measured with a commercially available reagent (EAC, Cordis Corp., Miami, Fla.) by a previously reported method (18) . At the end of these procedures, cells were spun in a cytocentrifuge and Giemsa stained. The morphology of the rosetteforming cells was determined by microscopic examination and the percentage of lymphoblasts forming E and EAC rosettes counted. In all patients with T-cell ALL, > 10% of the lymphoblasts formed E rosettes, while 0-1% of the lymphoblasts from individuals considered to have null-cell disease formed E rosettes. Thus, delineation of patients into these two categories is consistent with previously described criteria for the immunological subclassification of patients with ALL (19) .
RESULTS
The results of measuring ADA activity in the lymphoblasts of 23 ALL patients, and the lymphocytes from 10 controls are illustrated in Fig. 1 Lymphoblasts showed E-positive rosettes in 9 of the 23 patients. These individuals were classified as Tcell ALL. In all patients with T-cell disease, >10% of the lymphoblasts were E-rosette positive. In the other 14 patients, <1% of the lymphoblasts were E-rosette positive. These patients were classified as null-cell ALL. There were no B-cell ALL patients in this study. Fig. 1 also shows the ADA activity of individual patients grouped on the basis of cell surface markers. ADA activity in the T-cell ALL patients ranged from 32.0 to 161.5 ADA U/mg protein. The mean ADA activity was 3 times higher in T lymphoblasts (102 U) than in null lymphoblasts (30 U). This difference, when analyzed by the Wilcoxon rank-sum test, is highly significant (P < 0.02). 
DISCUSSION
In this study we have confirmed that ADA activity is elevated in acute leukemia lymphoblasts and that there is considerable variation in enzyme activity among different patients. Immunological and biochemical subclassification of these patients on the basis of their cell surface markers and ADA levels demonstrated a highly significant positive correlation between T-cell ALL and high ADA activity.
With current therapy, approximately 50% of ALL patients may expect to survive disease free for 5 yr or more (20) . Such encouraging results make it important to establish the prognosis for individual patients at the onset of treatment, particularly if it becomes possible to identify patients in a poor-prognostic category for whom different and more intensive therapy may be indicated (1) . It has been shown that 20-25% of ALL patients have T-cell surface markers, and that these patients respond less well to therapy than the larger proportion of patients with null-cell ALL (21) . Because the presence of high levels of ADA correlates with T-cell leukemia, determination of ADA activity in the lymphoblast cells of newly diagnosed ALL patients offers a simple and rapid technique to identify patients with a less favorable^,.rgnosis.
Although the reasons for the high ADA levels in Tcell lymphoblasts are not known, this phenomenon may be therapeutically exploitable. Recently, it has been shown that inhibition of lymphocyte ADA impairs lymphocyte function in vitro (2) , and causes lymphocytotoxicity in vivo (22) . The use of such potent inhibitors of ADA as coformycin (2) and 2'-deoxycoformycin (23) may provide a new and specific approach to the therapy of T-cell ALL, a disease which is usually resistant to currently available chemotherapy.
